Related Experiment Video
Updated: Jun 20, 2026
10:44
Mass Spectrometry and Luminogenic-based Approaches to Characterize Phase I Metabolic Competency of In Vitro Cell Cultures
Published on: March 28, 2017
Structure, function, regulation and polymorphism of human cytochrome P450 2A6
Yuan Ming Di1, Vivian Deh-Wei Chow, Li-Ping Yang
1Discipline of Chinese Medicine, School of Health Sciences, RMIT University, Victoria 3083, Australia.
Current Drug Metabolism
|August 26, 2009
Summary
The CYP2A6 enzyme is crucial for metabolizing drugs, toxicants, and procarcinogens. Genetic variations in CYP2A6 significantly impact drug clearance, smoking behavior, and cancer risk, highlighting its clinical importance.
Area of Science:
- Pharmacogenomics
- Drug Metabolism
- Toxicology
Background:
- The CYP2A6 gene, located on chromosome 19, encodes a hepatic Phase I enzyme vital for metabolizing numerous therapeutic drugs, environmental toxicants, and procarcinogens.
- CYP2A6 plays a significant role in the biotransformation of endogenous compounds like retinoids and steroids.
- Given its responsibility for 70-80% of nicotine metabolism, CYP2A6 is a potential target for smoking cessation therapies.
Purpose of the Study:
- To elucidate the structural and functional aspects of the CYP2A6 enzyme, including substrate recognition and active site characteristics.
- To investigate the regulatory mechanisms governing CYP2A6 expression, involving nuclear receptors.
- To summarize the known inhibitors of CYP2A6 and the significant interindividual variability in its activity.
Main Methods:
- Analysis of site-directed mutagenesis and homology modeling to identify key amino acids in substrate binding.
- Examination of crystal structure to understand active site features and substrate orientation.
- Review of existing literature on CYP2A6 regulation, inhibition, genetic polymorphisms, and associated clinical outcomes.
Main Results:
- Key amino acids (e.g., F300, A301, S208, S369, L370) and the enzyme's compact, hydrophobic active site with Asn297 were identified as critical for substrate recognition and oxidation.
- Nuclear receptors such as CAR, PXR, and GR are implicated in CYP2A6 gene expression regulation.
- Significant interindividual variability (20- to >100-fold) in CYP2A6 activity, primarily due to over 36 identified genetic polymorphisms (variant alleles *1B-*37) and influenced by drugs, environmental, and pathological factors.
Conclusions:
- CYP2A6 genetic polymorphisms are a major determinant of its activity, influencing drug clearance, smoking behavior, and lung cancer risk.
- Understanding CYP2A6 structure, function, and regulation is essential for its application in clinical practice, drug development, and toxicological assessments.
- Further research is warranted to fully explore the clinical implications of CYP2A6 variability.
Related Concept Videos
01:28Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes
Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...
01:27Pharmacogenetics of Drug Metabolism: Overview
Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
01:27Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
01:17Drug Metabolism: Phase I Reactions
A phase I reaction is a biochemical process that introduces a functionally reactive polar group to a substance. This transformation predominantly occurs in the liver, facilitated by the cytochrome P450 system of hemoproteins situated in the lipophilic endoplasmic reticulum of cells. The metabolite generated through this process can have varying polarities. If it is sufficiently polar, it can be easily excreted in the urine due to its water compatibility. However, if the metabolite is nonpolar,...